Luca Richeldi

Dec 4, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease associated with a decline in lung function and early mortality. In a phase II trial, treatment with the oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in lung function over 12 weeks and had an acceptable safety profile in patients with IPF, regardless of background use of antifibrotics, supporting phase III clinical development.

Oct 22, 2024 | emjreviews.com | Eva Polverino |Marc Miravitlles |Luca Richeldi |Franziska Trudzinski

Clinical Aspects and Diagnosis of BronchiectasisBronchiectasis is a clinical condition defined as a chronic, abnormal dilation of the bronchi accompanied by classical symptoms.1,2 While the disease typically develops from chronic airway inflammation and/or infection, it has multiple aetiologies (excluding cystic fibrosis, which is considered a separate clinical entity) that can be associated with several different conditions (Figure 1).1,3Figure 1: Major known causes of bronchiectasis.

Jun 27, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Methods and analysisThis multicentre, double-blind, randomised, placebo-controlled trial is investigating the efficacy and safety of BI 1015550 in patients with IPF stratified by use of background antifibrotics over at least 52 weeks (EudraCT: 1305-0014; ClinicalTrials.gov: NCT05321069). The trial began in September 2022 and is estimated to complete in November 2024.

Dec 22, 2023 | inria.hal.science | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Article Dans Une Revue BMJ open respiratory research Année : 2023 Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF) Fichier principal 2023_Richeldi_BMJ_Open_Respiratory_Research.pdf (1.03 Mo) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte Licence : CC BY - Paternité hal-04360963 , version 1 (22-12-2023) Luca Richeldi, Arata Azuma, Vincent Cottin, Michael...

Jul 13, 2023 | tandfonline.com | Luca Richeldi

References Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197. View PubMed Web of Science ®Google Scholar Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. View PubMed Web of Science ®Google Scholar Martinez FJ, Safrin S, Weycker D, et al.